



Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an antifibrotic agent

QUÉBEC, Québec, February 19, 2025 – Devonian Health Group Inc. (“**Devonian**” or the “**Company**”) (TSXV: **GSD**; OTCQB: **DVHGF**), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces the filing of a new patent application directed to the use of Thykamine™ as an antifibrotic agent.

Backed by *in vivo* data, the patent application displays the potential effectiveness of thylakoid extracts in treating and slowing the progression of fibrosis, and in down regulating several genes associated with fibrogenesis in several organs and tissues.

“The filing is timely as it supports the potential use of Thykamine™ in treating fibrotic diseases expanding therefore its therapeutic applications. This new patent application is another pivotal component of our broad strategy of expanding our list of patents.” said Dr. André P. Boulet, Chief Scientific Officer of the Company.

About Fibrosis^{1,2,3}

Fibrosis is a complicated physiological process that includes both acute and long-term inflammatory conditions. It is distinguished by an overabundance of fibrous connective tissue accumulating in and around injured or inflammatory tissues, leading to the formation of long-lasting scars. Fibrosis is the last stage of chronic disease in a number of organs, including the skin, heart, lungs, gut, liver, and kidneys. Increased morbidity and mortality result from the loss of structural integrity and function caused by fibrotic tissue pathologic accumulation.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of *in vitro* and *in vivo* studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult



patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Group L.P., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the-art extraction facility with full traceability "from the seed to the pill". Devonian is traded publicly on the TSX Venture Exchange (the "**Exchange**") (**TSXV: GSD**) and on **OTCQB** exchange (**OTCQB: DVHGF**).

For more information, visit www.groupedevonian.com

References

1. Gu Chang, Shi X, Dang X, et al. Identification of Common Genes and Pathways in Eight Fibrosis Diseases, *Frontiers in genetics*, Jan 15 (11), art 627396, 2021.
2. Ihn H. Pathogenesis of fibrosis: role of TGF- β and CTGF. *Curr Opin Rheumatol*, 14(6):681-85, 2002.
3. Steen EH, Wang X, Balaji S, et al. The role of the anti-inflammatory Cytokine Interleukin-10 in Tissue Fibrosis. *Advances In Wound Care*, 9 (4); 184-198, 2019.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including but, not limited to those relating to the economic impact of clinical study, the



efficiency of the highly anti-inflammatory potency proven and the position of the Thykamine™ as a possible first-line treatment of choice for several autoimmune conditions in the early stages of the disease and the reduced need for aggressive treatments with biological and other immune modulators, that are associated with serious side effects and long-term negative consequences, and, generally, the above “About Devonian” and “About Altius” paragraphs, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.



CONTACTS:

Devonian Health Group Inc.

Mr. Luc Gregoire

President & CEO

Dr. Andre P. Boulet, PhD

Chairman, Chief Scientific Officer

Telephone: 1 (450) 979-2916

E-mail: investors@groupe-devonian.com

Renmark Financial Communications Inc.

Mr. Ben Ozerkevich

Telephone: (416) 644-2020 or (212) 812-7680

E-mail: bozerkevich@renmarkfinancial.com

www.renmarkfinancial.com